NCT01142154已完成1 期
A Phase I/II Crossover Study To Evaluate and Compare the Pharmacokinetics of a Single IV Dose of D-Mannitol (Osmitrol®10%) to Single and Multiple, Escalating Doses of Liquid, Oral Prodarsan™ in Patients With Cockayne Syndrome
DNage B.V.1 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2010年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- Evaluate and compare the pharmacokinetics of D-mannitol following a single IV dose of Osmitrol to single and multiple oral doses of Prodarsan in pediatric patients with Cockayne Syndrome
研究概览
简要总结
This study is to compare the exposure of orally administered Prodarsan to the intravenous dosed Osmitrol (10% solution) in Cockayne Syndrome (CS) patients. Also the pharmacokinetics of single and multiple orally dosed Prodarsan will be evaluated and compared to intravenous dose of Osmitrol in CS patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 10 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Parents or legal guardian(s) of the pediatric patient with CS must be willing and able to give written Informed Consent. Informed Assent will be offered to children who can understand and participate in the Informed Assent process.
- •Diagnosis of CS confirmed by one of the following laboratory diagnostic test results:
- •Demonstration by molecular diagnostic analyses of two mutations in either the ERCC6 gene or the ERCC8 gene, wherein both mutations are either known to be pathogenic or are obviously detrimental (including nonsense or frameshift mutations, mutations of "invariant" splice site consensus signals, or large deletions/rearrangements); OR
- •A pattern of DNA repair responses in patient's cultured skin fibroblast cells indicative of a specific deficiency of transcription-coupled DNA nucleotide excision repair after irradiation with ultraviolet light, namely a significant deficiency of cellular survival (and/or "recovery of ribonucleic acid [RNA] synthesis," if that has been specifically measured) coupled with a normal test for "unscheduled DNA synthesis" OR
- •Decreased cell survival and/or "recovery of RNA synthesis" in UV-irradiated patient's skin fibroblast cultures and rescue of these parameters by fusion to reference cell lines with known NER defects (functional complementation analysis) OR
- •Quantitative RT-PCR to quantify mRNA levels of CS-A and CS-B transcripts.
- •Weight inclusive of 10 kg to 25 kg.
- •Male or female, inclusive of two (2) to ten (10) years of age.
- •Clinically acceptable hematocrit as judged by the Principal Investigator (PI).
- •The investigator has the opinion that the patient and caregiver are willing and able to comply with protocol requirements.
排除标准
- •Any concurrent illness (other than related to CS), disability or clinically significant abnormality, including laboratory tests, that may affect the interpretation of the PK or safety data or prevent the patient from safely completing the assessments required by the protocol as judged by the investigator. Such conditions include, but are not limited to:
- •Ascites or generalized edema.
- •Nephrotic syndrome or history of abnormal kidney function.
- •Clinically significant thyrotoxicosis.
- •Known history of hyperprolinemia.
- •Clinically significant dehydration as judged by the investigator
- •Severely compromised venous access.
- •Presence of an external ventricular, abdominal, or chest drain.
- •Subjects due to receive radioiodine therapy, two (2) weeks before or two (2) weeks following the study period.
- •Participation in another PK or treatment clinical study within thirty (30) days prior to signing and dating of Informed Consent/Assent Form for this study.
- •As judged by the investigator, clinical features present at the time of initial screening, that are associated with the terminal phases of the natural progression of CS, indicating that safe travel and completion of the study and its assessments are unlikely, including any of the following:
- •Continuous or intermittent dependence on supplemental oxygen at home during the six (6) months prior to enrollment in this study; OR
- •Two or more hospitalizations due to pneumonia, during the twelve (12) months prior to enrollment in this study; OR
- •A documented, net weight loss of at least 10%, which has not been recovered, and which includes a significant net weight loss (beyond the estimated error of the measurement) over the most recent 6 months despite intensive nutritional support including the use of gastrostomy tube feedings.
- •Known hypersensitivity to any of the components found in Prodarsan, D-mannitol, iohexol or iodine compounds.
- •History of clinically significant drug sensitivity or allergic reaction such as anaphylaxis.
研究组 & 干预措施
oral, liquid solution
Experimental
干预措施: Prodarsan (Drug)
结局指标
主要结局
Evaluate and compare the pharmacokinetics of D-mannitol following a single IV dose of Osmitrol to single and multiple oral doses of Prodarsan in pediatric patients with Cockayne Syndrome
时间窗: 6 months
次要结局
- Evaluate the safety and tolerability of administering oral Prodarsan in CS patients over a six (6) to eight (8) day period, including dose escalation to reach a Target Dose(6 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg TabletsHealthy Adult ParticipantsNCT03437564Takeda28
已完成
1 期
A Bioequivalence Study of TAK-536 Pediatric FormulationJapanese Healthy Adult MalesNCT02401464Takeda52
已完成
1 期
A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healthy Adult ParticipantsHealthy ParticipantsNCT05579860Ionis Pharmaceuticals, Inc.104
已完成
1 期
A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513)Chronic Hepatic ImpairmentNCT01465412Merck Sharp & Dohme LLC42
Unknown
1 期
PK/PD Study of Intranasal Insulin in Type I DiabetesType 1 DiabetesNCT01201278Hompesch, Marcus, M.D.20